Jasper Therapeutics, Inc.
JSPR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001788028
No open-market purchases or sales by Jasper Therapeutics, Inc. insiders were filed in the last 90 days; 45 institutions reported holding it in 13F filings for Q2 2026, worth $5.05M in total; no superinvestor holds it.
Other share classesJSPRW
Q2 2022 vs. Q1 2022
How the institutions holding Jasper Therapeutics, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 24 | 23 | −1 |
| Shares | 20.1M | 19.9M | −159.4K (−0.8%) |
| Value | $69.6M | $37.5M | −$32.1M (−46.1%) |
New holders (5)
Institutions that held Jasper Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Two Sigma Securities, LLC | 16,832 | $32.0K | 0.01% |
| UBS Group AG | 5,539 | $11.0K | 0.00% |
| Royal Bank of Canada | 2,555 | $5.00K | 0.00% |
| Group One Trading, L.P. | 400 | $1.00K | 0.00% |
| Citigroup Inc | 195 | $0 | 0.00% |
Sold out (6)
Institutions that held Jasper Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Federated Hermes, Inc. | 251,697 | $894.0K |
| Renaissance Technologies LLC | 10,871 | $39.0K |
| Vahanian & Associates Financial Planning Inc. | 10,000 | $36.0K |
| Highbridge Capital Management LLC | 741 | $3.00K |
| Ionic Capital Management LLC | 100 | $0 |
| SkyView Investment Advisors, LLC | 5 | $0 |